News
Press ReleaseRevive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study
Revive Therapeutics nears completion of critical nerve agent countermeasure study with Canada’s DND, unlocking major stockpiling potential.
Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity
Revive Therapeutics nears completion of critical nerve agent countermeasure study with Canada’s DND, unlocking major stockpiling potential.
Revive Therapeutics Advances with Next-Generation Bucillamine Development
Revive Therapeutics advances next-gen lyophilized Bucillamine for infectious diseases, nerve agent exposure, and potential cancer therapy.
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
Revive Therapeutics is collaborating with Defence R&D Canada to evaluate Bucillamine as a potential treatment for nerve agent exposure, aiming for FDA and Health Canada approvals.
Revive Therapeutics Announces Proposed Shares for Debt Transaction
Revive Therapeutics proposes a shares-for-debt transaction to settle outstanding liabilities, aiming to strengthen its financial position and reduce debt.
Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment
Revive Therapeutics explores Bucillamine as a cancer therapy with a top U.S. cancer institute, backed by NIH/government funding. Results expected soon.